Status:
COMPLETED
A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Patients with pancreatic cancer are treated with combinations of surgery, radiation therapy and chemotherapy, depending on the location of the cancer and other individual patient health factors. The g...
Detailed Description
Patients with pancreatic cancer are treated with combinations of surgery, radiation therapy and chemotherapy, depending on the location of the cancer and other individual patient health factors. The g...
Eligibility Criteria
Inclusion
- Patients with histologic or cytologic proof of pancreatic cancer, for whom the treatment plan, at the time of enrollment, is neoadjuvant chemoradiotherapy followed by surgical resection.
- Patients must be \>18 years old.
- Patients cannot weight over 300 pounds, the weight limit of the MRI table.
- Patients must have adequate renal function (estimated glomerular filtration rate \> 60 mL/min/m2), to minimize the small risk of nephrogenic systemic sclerosis associated with gadolinium injection.
- Patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of UM hospital.
Exclusion
- Patients must have no previous radiation to the abdomen.
- Patients who are pregnant or lactating are excluded.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 26 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01209962
Start Date
May 1 2008
End Date
May 26 2015
Last Update
July 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109